Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research

Consortium for Food Allergy Research investigators previously reported 52-week outcomes from a randomized controlled trial of peanut epicutaneous immunotherapy, observing modest and statistically significant induction of desensitization, highest in children ages 4 to 11 years. We sought to evaluate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2021-03, Vol.147 (3), p.992-1003.e5
Main Authors: Scurlock, Amy M., Burks, A. Wesley, Sicherer, Scott H., Leung, Donald Y.M., Kim, Edwin H., Henning, Alice K., Dawson, Peter, Lindblad, Robert W., Berin, M. Cecilia, Cho, Christine B., Davidson, Wendy F., Plaut, Marshall, Sampson, Hugh A., Wood, Robert A., Jones, Stacie M.
Format: Article
Language:English
Subjects:
2S Albumins, Plant - immunology
Adolescent
Adult
Age
Age Factors
Antigens, Plant - immunology
Arachis - immunology
Child
Child, Preschool
Consortia
desensitization
Desensitization (Psychology)
Drug dosages
epicutaneous immunotherapy
Female
follow-up
Follow-Up Studies
Food allergies
food allergy
Humans
IgE
IgG4
Immunoglobulin G
Immunoglobulin G - blood
Immunotherapy
Immunotherapy - methods
Injections, Subcutaneous
Male
Peanut allergy
Peanut Hypersensitivity - diagnosis
Peanut Hypersensitivity - immunology
Peanut Hypersensitivity - therapy
Placebos
Prognosis
Proteins
Statistical analysis
Success
Young Adult
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!